Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 925 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hepatitis C Clear all
Completed Not applicable Interventional

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

NCT00100581
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Results available

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

NCT00087607
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, Peginterferon alfa-2b (PEG-Intron), Peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 21, 2026, 6:57 PM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

NCT00882193
View directory record Official record
Conditions
Chronic Hepatitis C, Genotype 1, Relapse
Interventions
Betaine, Peginterferon alpha 2a, Ribavirin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.

NCT01277692
View directory record Official record
Conditions
Hepatitis C
Interventions
GSK2336805 10mg, GSK2336805 30mg, GSK2236805 100mg, GSK2236805 200mg, GSK2236805 10mg, GSK2236805 dose to be determined up to 100mg, GSK2236805 5mg, GSK2236805 30mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Chula Vista, California • Lenexa, Kansas • Willingboro, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 21, 2026, 6:57 PM EDT
Terminated No phase listed Observational

Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma

NCT00767936
View directory record Official record
Conditions
Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver, Hepatobiliary Cancers
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 4 Interventional

Pioglitazone in Hepatitis C

NCT00189163
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pioglitazone, Placebo Oral Tablet
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction & Methadone & Buprenorphine

NCT02045693
View directory record Official record
Conditions
Hepatitis C
Interventions
Methadone, DCV 3DAA FDC, BMS-791325, Buprenorphine, Naloxone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
3
States / cities
Anaheim, California • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients

NCT04198584
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
VC-CBCS
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus

NCT02098616
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV/ASV/BMS-791325, DCV/ASV/BMS-791325 + RBV
Drug
Lead sponsor
Timothy Morgan, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 21, 2026, 6:57 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs

NCT04395118
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Mailed Outreach
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Bridging Active Heroin Users to Hepatitis C Treatment Using Buprenorphine - 1

NCT00249574
View directory record Official record
Conditions
Hepatitis C, Heroin Dependence
Interventions
Buprenorphine/naloxone, pegInterferon
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Multiple Ascending Dose Study of Miravirsen in Treatment-Naïve Chronic Hepatitis C Subjects

NCT01200420
View directory record Official record
Conditions
Hepatitis C
Interventions
miravirsen, saline
Drug
Lead sponsor
Santaris Pharma A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 21, 2026, 6:57 PM EDT
Completed No phase listed Observational

Project BEST: Buprenorphine Entry Into Substance Abuse Treatment

NCT02583243
View directory record Official record
Conditions
Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
Interventions
MET/CBT based individualized counseling, Buprenorphine
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 21, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional Results available

Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis C

NCT01532908
View directory record Official record
Conditions
Hepatitis C Infection
Interventions
MBL-HCV1, Telaprevir (Part 1), Sofosbuvir (Part 2)
Biological · Drug
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

NCT04710641
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatitis B, Hepatitis C
Interventions
MTL-CEBPA, Sorafenib
Drug
Lead sponsor
Mina Alpha Limited
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

NCT01859962
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PPI-668, BI 207127 Dose 1, BI 207127 Dose 2, Faldaprevir, Ribavirin, BI 207127 Placebo
Drug
Lead sponsor
Presidio Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325

NCT02095860
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV 3DAA FDC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection

NCT02593162
View directory record Official record
Conditions
Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 4
Interventions
Faldaprevir, TD-6450, Ribavirin
Drug
Lead sponsor
Trek Therapeutics, PBC
Industry
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coronado, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 21, 2026, 6:57 PM EDT
Completed No phase listed Observational

Leukapheresis for Research on HCV-Coinfected Patients

NCT00076427
View directory record Official record
Conditions
Hepatitis C, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 21, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional Results available

Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C

NCT01121185
View directory record Official record
Conditions
HCV Infection, Liver Transplantation
Interventions
MBL-HCV1, 0.9% Sodium chloride Placebo
Biological · Other
Lead sponsor
MassBiologics
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
New Haven, Connecticut • Boston, Massachusetts • Burlington, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2016 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Patient-Centered Models of HCV Care for People Who Inject Drugs

NCT02824640
View directory record Official record
Conditions
Hepatitis C, Medication Adherence
Interventions
Patient Navigation, modified Directly Observed Therapy
Behavioral
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years to 70 Years
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

NCT03420768
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis
Interventions
BMS-986263, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 21, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Hepatitis C-Video vs. Brochure Education Delivery

NCT04204447
View directory record Official record
Conditions
Hepatitis C
Interventions
Hepatitis C Educational Brochure, Hepatitis C Educational Video
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Buffalo, New York • Orchard Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 6:57 PM EDT
Completed No phase listed Observational

Prevalence of Hepatitis C Virus Infection in HIV-Infected Children

NCT00037076
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 20 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 21, 2026, 6:57 PM EDT